每经AI快讯，蓝帆医疗（SZ 002382，收盘价：5.73元）11月28日晚间发布公告称，公司第六届第三十 四次董事会会议于2025年11月28日以通讯表决的方式召开。会议审议了《关于召开2025年第六次临时股 东会的议案》等文件。 2025年1至6月份，蓝帆医疗的营业收入构成为：橡胶和塑料制品业占比70.08%，专用设备制造业占比 24.88%，其他制造业占比3.72%，其他业务占比1.32%。 截至发稿，蓝帆医疗市值为58亿元。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 （记者 曾健辉） ...

人民财讯11月28日电，蓝帆医疗（002382）11月28日公告，截至2025年11月28日，公司股价已出现连续 三十个交易日中至少有十五个交易日的收盘价低于当期转股价格85%的情形，已触发"蓝帆转债"转股价 格向下修正条件。经公司第六届董事会第三十四次会议审议通过，公司董事会提议向下修正"蓝帆转 债"转股价格。 修正后的转股价格应不低于该次股东会召开日前二十个交易日公司股票交易均价和前一个交易日公司股 票交易均价之间的较高者，且同时不得低于最近一期经审计的每股净资产值以及股票面值。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-093 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于董事会提议向下修正"蓝帆转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 11 月 28 日，蓝帆医疗股份有限公司（以下简称"公司"）股价 已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情 形，已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第三十四次会议审议通过，公司董事会提议向下修正 "蓝帆转债"转股价格。 3、本次向下修正"蓝帆转债"转股价格的提议尚需提交公司股东会审议。 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值100 元，发 行总额314,404 万元。 ...

2、股东会的召集人：董事会 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于召开2025年第六次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第三 十四次会议审议通过，公司决定于 2025 年 12 月 15 日召开 2025 年第六次临时股东 会，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第六次临时股东会 7、出席对象： （1）截至 2025 年 12 月 4 日（星期四）下午收市时在中国证券登记结算有限责 任公司深圳分公司登记在册的本公司全体股东。上述股东可亲自出席股东会，也可 以以书面形式委托代理人出席会议和参加表决，该股东代理人不必是本公司股东。 3、会议召开的合法、合规性：本次召开股东会的议案经公司第六届董事会第三 十四次会议审议通过。本次股东会的召集、召开符合《中华人 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-092 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第三十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 具体内容详见刊登于公司指定的信息披露媒体《中国证券报》、《上海证券报》、《证 券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）上的《关于董事会提 议向下修正"蓝帆转债"转股价格的公告》。 2、审议并通过了《关于召开 2025 年第六次临时股东会的议案》。 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十四次会议于 2025 年 11 月 24 日以电子邮件的方式发出通知，于 2025 年 11 月 28 日以通讯表决的方式召 开。本次会议应参加会议董事 8 人，实际参加会议董事 8 人，全体董事以通讯的方式 出席会议。公司董事长刘文静女士主持 ...

Core Insights - The endovascular neurointervention for cerebral infarction has experienced explosive growth in China, driven by an aging population and lifestyle changes, leading to a continuous rise in the incidence of cerebral infarction [1][4][12] - The number of endovascular neurointervention procedures is projected to increase significantly, reaching 182,500 in 2024 and 266,600 in 2025 [1][5][4] Industry Definition and Barriers - Cerebral infarction, or acute ischemic stroke (AIS), accounts for approximately 80% of all strokes, primarily affecting individuals aged 45 to 70, with an increasing proportion of younger patients [2][4] - The industry has significant talent and brand barriers, as it requires specialized medical knowledge and substantial funding for product development and market entry [3][4] Current Industry Development - The endovascular neurointervention market has seen a rise from 24,100 procedures in 2017 to 182,500 in 2024, with expectations to reach 266,600 by 2025 [4][5] - The breakdown of procedures in 2024 includes intracranial stent retrieval (84,400 procedures, 46.25%), intracranial thrombectomy (66,500 procedures, 36.44%), and other procedures (31,600 procedures, 17.32%) [5] Industry Chain Structure - The industry chain includes upstream raw materials, production and diagnostic equipment, and professional support services, which influence the overall operation of the midstream device manufacturing and downstream clinical treatment [4][6] Major Companies - Key players in the market include Weikang Medical, Xinyi Medical, and Guichuang Tongqiao, among others, with increasing competition as demand grows [8][9] - Microinvasive Brain Science has established a comprehensive product line for stroke intervention, achieving significant revenue growth from 80 million yuan in 2019 to 402 million yuan in 2024 [9] - Guichuang Tongqiao reported a revenue of 780 million yuan in 2024, a 48.3% increase year-on-year, with a gross profit of 560 million yuan [9][10] Industry Development Trends - The market is expected to grow due to rising economic levels, lifestyle changes, and an aging population, with significant opportunities for domestic device manufacturers [12][13] - The industry is expanding its application range, moving beyond ischemic and hemorrhagic strokes to include complex lesions and combinations with other treatment methods [12][13]

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 10.00 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 （二）可转债上市情况 经深圳证券交易所（以下简称"深交所"）"深证上〔2020〕523 号"文同意，公司 314,404 万元可转债于 2020 年 6 月 19 日起在深交所挂牌交易，债券简称"蓝帆转债"，债券代 码"128108"。 （三）可转债转股期限 根据《蓝帆医疗股份有限公司公开发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）的规定，本次发行的可转债转股期自可转债发行结束之日（2020 年 6 月 3 日 ...

Core Viewpoint - The company, Bluestar Medical (002382), confirmed that its production and operational activities are normal and have not triggered any risk warnings or delisting risk warnings according to the relevant regulations of the Shenzhen Stock Exchange [1] Group 1 - The company responded to investor inquiries on November 14, indicating compliance with stock exchange regulations [1] - There are currently no events that would lead to risk warnings or delisting risks for the company [1]

Group 1 - The core point of the article is that as of October 31, 2025, the number of shareholders for Bluestar Medical (002382) is projected to be 74,338 households [1]

Core Viewpoint - The company, Bluestar Medical, reported a decline in revenue and profit for the first three quarters of 2025, primarily due to challenges in its health protection division, particularly in glove production [1] Group 1: Revenue and Profit Decline - The decline in revenue and profit is mainly attributed to the health protection division, with significant impacts from the PVC glove segment due to tariff and cyclical pressures [1] - The global glove industry is experiencing historically low pricing, prompting the company to adjust its operational strategy to increase order prices, resulting in improved gross margins despite lower revenue [1] Group 2: Cost Management - The company has not increased its expenses; instead, total sales, management, and R&D expenses decreased by over 60 million yuan year-on-year, indicating successful cost reduction measures implemented since last year [1] Group 3: Strategic Initiatives - The management is actively addressing challenges posed by the new international trade environment through various strategies, including supply chain enhancements, product innovation, and efficiency improvements [1] - The cardiovascular division has seen significant revenue and profit growth, reflecting the company's past investments in high-value consumables and its efforts to build an international platform [1] Group 4: Future Outlook - The company plans to continue advancing its strategic initiatives across various segments, focusing on product development and market expansion to enhance operational efficiency and deliver satisfactory results [1]